Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01316432Phase 1Completed

PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients

Role: lead

NCT00839007Phase 2Completed

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

Role: lead

NCT00699712Phase 2Completed

Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)

Role: lead

NCT00557661Phase 1Completed

Safety Study of CD-NP in Heart Failure

Role: lead

NCT00482937Phase 1Completed

Safety and Pharmacodynamic Study of CD-NP

Role: lead

All 5 trials loaded